388
Participants
Start Date
October 31, 2002
Study Completion Date
January 31, 2004
Rosiglitazone
spironolactone
hydrochlorothiazide
frusemide
GSK Investigational Site, Brussels
GSK Investigational Site, Hellerup
GSK Investigational Site, Sint-Gillis-Waas
GSK Investigational Site, Athens
GSK Investigational Site, Genoa
GSK Investigational Site, Milan
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Bologna
GSK Investigational Site, Neuss
GSK Investigational Site, Dommartin-lès-Toul
GSK Investigational Site, Mainz
GSK Investigational Site, Blieskastel
GSK Investigational Site, Heidelberg
GSK Investigational Site, Acquavive Delle Fonti (BA)
GSK Investigational Site, Paris
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Winnipeg
GSK Investigational Site, Aarhus
GSK Investigational Site, Hvidovre
GSK Investigational Site, Dresden
GSK Investigational Site, N. Efkarpia, Thessaloniki
GSK Investigational Site, Nikaia Piraeus
GSK Investigational Site, Jerusalem
GSK Investigational Site, Oslo
GSK Investigational Site, Tromsø
GSK Investigational Site, Olsztyn
GSK Investigational Site, Alicante
GSK Investigational Site, Newcastle upon Tyne
GSK Investigational Site, London
GSK Investigational Site, Perugia
GSK Investigational Site, Utrecht
GSK Investigational Site, Stavanger
GSK Investigational Site, Bialystok
GSK Investigational Site, Krakow
GSK Investigational Site, Lodz
GSK Investigational Site, Warsaw
GSK Investigational Site, Bratislava
GSK Investigational Site, Košice
GSK Investigational Site, Ľubochňa
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, Tarrasa, Barcelona
GSK Investigational Site, Rugby
Lead Sponsor
GlaxoSmithKline
INDUSTRY